Bio-Techne (TECH) said Thursday it expanded an agreement with Oxford Nanopore Technologies, allowing it to develop a portfolio of genetic products on Oxford platforms.
The company said it was granted expanded commercial rights to develop a portfolio of sequencing kits to screen and diagnose heritable genetic disorders.
Bio-Techne said its collaboration with Oxford is extended through 2032 under the expanded agreement, which also establishes a framework to define and propose future portfolios.